JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri




focus

author：knowledge    Page View：4161

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

  • Irena Melnikova, Ph.D., partner, Pfizer Ventures
  • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
  • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Mayo Clinic partners with supercomputer AI firm Cerebras at JPM
Next article： Medicare proposal to cover medical devices draws a mixed reaction